Latest action: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
Originating chamber has voted to pass. Sent to the other chamber.
The House voted to pass the bill. It now moves to the Senate, which repeats the committee referral and floor-vote process.
Next: Passed Both Chambers
Conference committee (if versions differ), then the President
Reauthorizes a program to help ALS patients access experimental treatments faster.
The problem
ALS patients need faster access to new therapies. Current approval processes take time. Patients with this deadly disease cannot wait.
The proposal
The bill extends and updates a program allowing ALS patients to try newer treatments before full FDA approval, speeding up their access to potential cures.
The impact
ALS patients gain quicker access to experimental drugs. Pharmaceutical companies can test treatments faster. Doctors have more options for treating this disease.
ALS patients can try promising new drugs sooner instead of waiting years for full approval. This gives terminally ill patients hope and potentially life-saving options they would otherwise never receive.
Pharmaceutical companies can gather real-world data on new treatments faster. This speeds up the entire drug development process and could lead to more cures reaching patients sooner.
The bill passed committee unanimously (46-0), showing broad agreement that ALS patients need help. This suggests the approach balances patient needs with safety concerns.
ALS affects relatively few people, so companies may not develop treatments without incentives. This program helps ensure rare diseases still get research attention and funding.
Faster approval means less testing data before patients use drugs. If a treatment is harmful, patients could be hurt before problems are discovered.
Experimental drugs may not actually work. Patients might spend time and money on treatments that provide false hope rather than real help.
Only some patients may qualify or afford experimental therapies. This could create unfair treatment where wealthy patients get access others cannot.
Faster processes may reduce the ability to monitor and regulate how treatments are used. Problems might be harder to catch and stop if needed.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.